Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real worldJun Sugisaka, Yasushi Honda, Yukihiro Toi et al.|Annals of Oncology|2019Cited by 4